Open AccessHERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma
Author(s) -
Josep Tabernero,
Lin Shen,
Elena Elimova,
Geoffrey Y. Ku,
Tianshu Liu,
Kohei Shitara,
Xiao Lin,
Lisa Boyken,
Huiyan Li,
Jonathan Grim,
Jaffer A. Ajani
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2022-0595
Subject(s) - medicine , trastuzumab , chemotherapy , oncology , gastroesophageal junction , monoclonal antibody , cancer , adenocarcinoma , antibody , immunology , breast cancer
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom